Welcome to DailyUpdates Cardiovascular disorders - the R&D community's bulletin of breaking research, clinical trials and drug development news. This page will update each day. You have access for 2 more day(s). To receive DailyUpdates by e-mail register here


PubMed DailyUpdates: Breaking Scientific Publications for the Drug Discovery Community

DailyUpdates by e-mail - the publication tracker for the drug discovery community

Cardiovascular disorders



If this icon appears after any of our listed articles, the author is able to provide reprints. Articles denoted by an Licensing Op. icon describe data relevant to licensing opportunities. The report icon, , links through to full analyses relating to pharmaceutical/market developments relating to this work

Today's journal articles

Mean platelet volume on admission correlates with impaired response to thrombolysis in patients with ST-elevation myocardial infarction.

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

Add-on Aliskiren Treatment in Patients With Chronic Congestive Heart Failure

Previous Journal Entries

Long-term outcomes following coronary drug-eluting- and bare-metal-stent implantation.

Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting.

Gabapentin (Neurontin(R)) improves pain scores of patients with critical limb ischaemia: An observational study.

Differential protein biomarker expression and their time-course in patients with a spectrum of stable and unstable coronary syndromes in the Integrated Biomarker and Imaging Study-1 (IBIS-1).

Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany.

Changes in secondary prevention of coronary artery disease in the post-discharge period over the decade 1997-2007. Results of the Cracovian Program for Secondary Prevention of Ischaemic Heart Disease and Polish parts of the EUROASPIRE II and III surveys.

Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial.

Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy.

Do atypical antipsychotic drugs reduce the risk of ischemic heart disease and mortality? Possible role of 5-HT2A receptor blockade.

Novel bis - arylsulfonamides and aryl sulfonimides as inactivators of plasminogen activator inhibitor - 1 (PAI - 1).

Synthesis and pharmacological evaluation of new 1-[3-(4-phenylpiperazin-1-yl)-propyl]- and 1-[3-(4-phenylpiperidine)-propyl]- 3-aryl-3-alkyl-pyrrolidin-2-one derivatives with antiarrhythmic and antihypertensive activity.

Effect of hydrogen sulfide on myocardial protection in the setting of cardioplegia and cardiopulmonary bypass.

A PKC-beta inhibitor protects against cardiac microvascular ischemia reperfusion injury in diabetic rats.

Dual antiplatelet therapy and antithrombotic treatment in patients with acute coronary syndrome - does everyday medical practice reflects current recommendations? A pilot study.

Switching of antihypertensive drugs among 93 286 Chinese patients: a cohort study.

In-hospital and mid-term clinical outcomes after percutaneous coronary intervention with the use of sirolimus- or paclitaxel-eluting stents.

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.

Association between off-label use of drug-eluting stents and subsequent stent thrombosis: a case-control analysis.

Site - specific labeling of 'second generation' annexin V with (99m)Tc(CO)(3) for improved imaging of apoptosis in vivo.

Discovery of a benzoxazine derivative promoting angiogenesis in vitro and in vivo.

Today's News Items

St. Jude Medical Announces European Approval of Smaller, Higher Power ICD and CRT-D Devices with New Heart Failure Monitors

Anthera Pharmaceuticals Announces Agreement with the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study

Training Courses & Meetings

No events listed

Previous News Items

St. Jude Medical Announces IRASE AF Clinical Trial to Evaluate Cardiac Ablation Catheter System for Treatment of Atrial Fibrillation

DAIICHI SANKYO INITIATES LARGEST SINGLE, DOUBLE-BLIND,RANDOMIZED, PHASE 3 TRIAL FOR TREATMENT AND PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM

Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel